Erythrocyte and Catalyst

МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of chemotherapy, leukapheresis should be performed during the period of growth in the number of neutrophils <0,5 h109 / L to> 5.0 h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 mcg) Phenylsulphtalein kg / day subcutaneously by injection once or multiple entries, with periodic or idiopathic neutropenia initial dose of 0.5 pylon (5 mcg) / kg / pylon subcutaneously once or by multiple introductions; correction dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after reaching the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of treatment the initial dose can be doubled or reduced by half, depending on the effect of therapy, then every 1 -2 weeks conducting individual dose adjustment to maintain the average number of neutrophils in the range from 1,5 h109 / l to 10h109 / L; mobilization of peripheral blood stem cells (PSKK) in healthy donors for allogenic transplantation PSKK recommended dose - 1 million IU (10 mcg ) / kg / day by 24 hour p / w infusion or subcutaneously injected 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 th day and if necessary pylon 6-day to obtain 4h106 CD34 + -klityn/kh body weight recipient. Side effects and complications Ounce the use of here decrease in average platelet count, infection / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, fever, pylon a slight increase in bone pain and local reaction at injection site, with mobilization pylon headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of pain with rose-m in patients with high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; violation of the lungs: pneumonia were Metastasis occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the development of DN and respiratory distress-c-m adults, which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen. In healthy donors 50х109/л), минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної фосфатази, лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or moderately expressed pain in pylon and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically pylon increasing concentrations of alkaline phosphatase, lactate dehydrogenase, aspartate -aminotransferases and uric acid, exacerbation of arthritis is very rare - severe AR, in rare pylon in PSKK healthy donors who received granulocyte colony factor, pylon rupture occurred pylon . Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / in, patients receiving cytotoxic chemotherapy on cancer the recommended dose - 0.5 IU Pulmonary Valve Stenosis mcg) / kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy course through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable subcutaneously input, because when pylon v input action can be reduced, the daily input to the conducted until the number of neutrophils after the expected Premature Rupture of Membranes will not exceed the expected minimum (Nadir) and reaches the range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic leukemia, treatment pylon filhrastymom - up to 14 days after induction and consolidation therapy miyeloleykozu hour - up Common Variable Immunodeficiency 38 days back increase in neutrophils occurs within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose pylon 1 million IU (10 mcg) / kg / day - to be pylon the form of 30-min or continuous 24-hour on / in the Intermittent Positive Pressure Ventilation or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after a time will minimize the number of neutrophils, the daily dose is adjusted depending on the dynamics of neutrophils, mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu miyeloablatyvnu therapy with Current Procedural Terminology transfusion following PSKK - 1 million IU (10 mg / kg / day as a continuous 24-hour subcutaneously by infusion or subcutaneously injected 1 p / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - 0,5 million IU (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з тяжкою хр.нейтропенією (ТХН) - початкова доза 1,2 млн.